Author(s)

ChongQi Fan, HuanWen Chen^*

Affiliation(s)

Department of Cardiothoracic Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.

Corresponding Author

HuanWen Chen

ABSTRACT

Non-small cell lung cancer (NSCLC) constitutes 80%-85% of all lung cancer cases. Epidemiological data reveal global variations in incidence, with rates increasing with age, higher prevalence in males, and a shift from squamous cell carcinoma to adenocarcinoma as the dominant subtype. Although the 5-year survival rate remains low, prognosis has shown gradual improvement. Advances in diagnostic technologies, including PET-CT and video-assisted biopsy techniques, have enhanced diagnostic precision. Current treatment strategies prioritize surgery-based multimodal regimens, complemented by personalized approaches. Targeted therapies and immunotherapies now offer novel therapeutic avenues for NSCLC patients.

KEYWORDS

Non-small cell lung cancer; Epidemiology; Clinical diagnosis and treatment; Therapeutic innovations

CITE THIS PAPER

ChongQi Fan, HuanWen Chen. Epidemiological characteristics and recent advances in clinical management of non-small cell lung cancer. World Journal of Clinical Sciences. 2025, 3(1): 11-15. DOI: https://doi.org/10.61784/wjcs3019.

REFERENCES

[1] Chen Y, Ji R, Zhang Z J, et al. Mechanism of Huangyaozi against non-small cell lung cancer based on network pharmacology and molecular docking. Chinese Journal of Clinical Pharmacology, 2025:1-4.

[2] Ma X T, Jia Z, Li H B, et al. Diagnostic efficacy of low-dose versus conventional-dose multi-slice spiral CT in elderly patients with non-small cell lung cancer. Chinese Journal of Gerontology, 2025, 45(5):1073-1075.

[3] Wang Y L, Rong F Y, Xia T, et al. Safety and efficacy of different doses of bevacizumab combined with pemetrexed disodium and cisplatin in elderly patients with advanced non-squamous non-small cell lung cancer. Chinese Journal of Gerontology, 2025, 45(5):1076-1080.

[4] Zhao H H, Xu Y R, Tian X A, et al. Expression and prognostic significance of Axl, Mer, and Gas-6 in non-small cell lung cancer. Chinese Journal of Gerontology, 2025, 45(5):1087-1091.

[5] Wu Y, Wang Y, Huang X, et al. Multimodal learning for non-small cell lung cancer prognosis. Biomedical Signal Processing and Control, 2025, 106:107663.

[6] Hirata M H, Lee B C, Chen Y K. Fam-Trastuzumab-Deruxtecan and Osimertinib Combination to Target HER2 Driven Resistance in a Patient With NSCLC After Osimertinib Progression: Case Report. JTO Clinical and Research Reports, 2025, 6(4):100787.

[7] Wei Y, Zhang Z, Ao T. Polymer composites with enhanced electrochemical properties and their application in non-small cell lung cancer treatment. Journal of Molecular Structure, 2025, 1334:141813.

[8] Rowe J D, Khalil A T, Kammer N M, et al. A deeper evaluation of cytokeratin fragment 21-1 as a lung cancer tumor marker and comparison of different assays. Biosensors and Bioelectronics: X, 2025, 23:100593.

[9] Saw P S, Takano A, Zhou S, et al. EGFR mutation status affects intra-tumoral heterogeneity of PD-L1 expression but not agreement between assays in resectable non-small cell lung cancer. Lung Cancer, 2025, 202:108463.

[10] Soo R, Vervita K, Früh M, et al. A randomized non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial. Lung Cancer, 2025, 202:108454.

[11] Rong D, Gao L, Chen Y, et al. Suppression of the LKB1-AMPK-SLC7A11-GSH signaling pathway sensitizes NSCLC to albumin-bound paclitaxel via oxidative stress. Redox Biology, 2025, 81:103567.

[12] Hu Y N, Chen C J, Liu Y S, et al. Cardiac effects of pharmacological therapy for EGFR-mutated non-small cell lung cancer. Journal of Clinical Electrocardiology, 2024, 33(3):206-210.

[13] D Gu. Efficacy and safety analysis of bevacizumab combined with chemotherapy in patients with advanced non-small cell lung cancer. Smart Healthcare, 2023, 9(9):207-211. DOI:10.19335/j.cnki.2096-1219.2023.09.047.

[14] M Y Zhou, S Yuan, Y Xiang, et al. Expression and cellular function of long non-coding RNA SFTA1P in non-small cell lung cancer tissues. Chinese Journal of Disease Control & Prevention, 2020, 24(3):341-347.

[15] Y H Wang, W J Xie, Y Xiang, et al. Functional study of long non-coding RNA OSER1-AS1 in non-small cell lung cancer cells. Journal of Third Military Medical University, 2020, 42(3):246-252.

[16] P M Kicken, J M Deenen, D V J A Wekken, et al. Opportunities for precision dosing of cytotoxic drugs in non-small cell lung cancer: Bridging the gap in precision medicine. Clinical Pharmacokinetics, 2025: (prepublished):1-21.

[17] A J Roth, D Kratochvil, S Dorman, et al. Cost-efficiency and expanded access modeling of conversion to biosimilar bevacizumab in metastatic colorectal and non-squamous non-small cell lung cancer in Medicare. Journal of Medical Economics, 2025, 11:11-16.

[18] D Shen, J Min, J Chen, et al. Study on the material basis and mechanisms of Achyrocline satureioides in the treatment of non-small cell lung cancer based on network pharmacology and spatial metabolomics. Analytical Chemistry, 2025.

[19] L Zhang, C X Li, H Y Peng, et al. Expression and significance of plasma exosomal hsa_circ_0052513 in non-small cell lung cancer. Cancer Research on Prevention and Treatment, 2024, 51(9):744-749.

[20] H T Xue, Q Liu, Y B Cui, et al. Predictive value of plateletcrit and CA242 for positive minimal residual disease detection in non-small cell lung cancer patients. Chinese Journal of Laboratory Diagnosis, 2024, 28(5):539-544.

[21] R X Cai, G R Zhou. Role of circulating tumor DNA in personalized therapy for non-small cell lung cancer. Chinese Journal of Clinical Research, 2024, 37(1):12-14,19. DOI:10.13429/j.cnki.cjcr.2024.01.003.

[22] Y L Zhou, L S Shen. Clinical applications and challenges of liquid biopsy biomarkers in non-small cell lung cancer. Laboratory Medicine, 2023, 38(9):807-811,806.

[23] C Q Chen, L F Ma, J Y Wang. Application of liquid biopsy in diagnosis and treatment of lung cancer. Practical Journal of Clinical Medicine, 2023, 20(5):18-21.

[24] W Q Miao, X H Lin, Z L Pang. Clinical application of liquid biopsy in individualized chemotherapy for small cell lung cancer. Jilin Medical Journal, 2023, 44(7):1795-1798.

[25] B Su, C Luo, X Xun. Expression of moesin and PAX1 in elderly non-small cell lung cancer tissues and their correlation with osimertinib-targeted therapy efficacy. China Medicine, 2025, 20(3):370-375.

[26] J T Lin, M Sun, K Y Ye, et al. Post-neoadjuvant SUVmax as a prognostic marker in operable non-small cell lung cancer. The Journal of Evidence-Based Medicine, 2025, 25(1):32-41.

[27] M F Yuan, Q Pu, B Zhao, et al. Impact of two Monaco optimization modes on stereotactic radiotherapy plans for non-small cell lung cancer. Clinical Journal of Biomedical Engineering, 2025:1-7.

[28] Y Q Wang, P H Song, Y D Xu, et al. Efficacy analysis of whole-brain radiotherapy versus local boost radiotherapy for oligometastatic brain lesions in non-small cell lung cancer. Chinese Journal of CT and MRI, 2025, 23(1):22-24.

[29] Y H Li, L Y Dong, Y Fang. Effect of photodynamic therapy combined with albumin-bound paclitaxel chemotherapy in non-small cell lung cancer. Chinese Journal of Health Engineering, 2025, 34(1):107-109+112.

[30] L Lin, H J Zhao, Q Q Li, et al. Clinical study of compound Kushen injection combined with tislelizumab and chemotherapy in advanced non-small cell lung cancer. Modern Drugs & Clinics, 2024, 39(11):2877-2882.

[31] S C Ji, X J Cui, Y H Sun, et al. Stent implantation combined with low-dose albumin-paclitaxel for small cell lung cancer with pulmonary artery stenosis: A case report. Journal of Interventional Radiology, 2024, 33(11):1252-1254.

[32] M Sattler, R Salgia. The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer. Cell Reports Medicine, 2025:101983.

[33] D D Fan, J Luo, Y Y Guo. Effects of osimertinib-targeted therapy on immune function and tumor cytokines in patients with advanced non-small cell lung cancer. Tianjin Pharmacy, 2025, 37(1):32-35.

[34] F F Zhao, Y Zheng, T T Niu, et al. Research progress on adverse reactions of antibody-drug conjugates in non-small cell lung cancer. Chinese Journal of Oncology Prevention and Treatment, 2025, 17(1):120-127.

[35] R Gao, H Zhao. Research progress on HER2-targeted antibody-drug conjugates for advanced non-small cell lung cancer. Journal of Community Medicine, 2025, 23(1):32-36. DOI:10.19790/j.cnki.JCM.2025.01.06.

[36] Y Qi, X Zhai, Q Xu, et al. Comparison of neoadjuvant chemoimmunotherapy with planned surgery and concurrent chemoradiation followed by immunotherapy for potentially resectable stage III non-small-cell lung cancer: A retrospective study. Cancer Immunology, Immunotherapy: CII, 2025, 74(4):119.

[37] T L Ren, Y Guo, Z Y Shi, et al. Research progress on pathogenesis, clinical characteristics, and treatment strategies of NRG1 gene fusion in non-small cell lung cancer. Shandong Medical Journal, 2025, 65(2):125-129.

[38] Q Xu, X Hua, B Li, et al. Intrinsic STING of CD8+ T cells regulates self-metabolic reprogramming and memory to exert anti-tumor effects. Cell Communication and Signaling, 2025, 23(1):99-99.

[39] L L Zhang, T T Wu, H Y Jia. A case of non-small cell lung cancer with rare EGFR mutation combined with MET amplification and PD-L1 high expression and literature review. Journal of Shanxi Medical University, 2025:219-222.

[40] W J Zhang, Z P Liang, A Zhang, et al. Characteristics of TCM syndromes and elements in hypothyroidism induced by immunotherapy for advanced non-small cell lung cancer. Journal of Guangzhou University of Traditional Chinese Medicine, 2025, 42(2):283-292.